Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Near Complete Response to Trametinib Treatment in Histiocytic Sarcoma Harboring a Somatic KRAS Mutation.

Journal of the National Comprehensive Cancer Network : JNCCN - 24 Mar 2022

Hu Boyu, Patel Jay L, Tao Randa, Cannon Richard B, Monroe Marcus, Goyal Gaurav

Abstract excerpt

Survival outcomes of patients with histiocytic neoplasms are poor, with no standard-of-care treatments available for these malignancies. Recent characterization of the genomic landscape of various histiocytic neoplasms have shown a predominance of activating driver mutations within the MAPK/ERK pathway (ie, BRAF, MEK, KRAS, MAPK, and NRAS). Subsequently, successful treatment of these malignancies with BRAF and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mitogen-Activated Protein Kinase Kinases
Share to Mutation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 35325867
DOI: 10.6004/jnccn.2022.7001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Near Complete Response to Trametinib Treatment in Histiocytic Sarcoma Harboring a Somatic KRAS Mutation.PMID 35325867Read ↗

Trametinib in Histiocytic Sarcoma with an Activating MAP2K1 (MEK1) Mutation.Semantic proximity Read ↗

Mutations in the Serine/Threonine Kinase BRAF: Oncogenic Drivers in Solid TumorsSemantic proximity Read ↗

Exceptional Response to MEK Inhibition in a Patient With RAF1-Mutant Myxofibrosarcoma: Case Report and Mechanistic OverviewSemantic proximity Read ↗

Efficacy of MEK inhibitors in Erdheim-Chester disease: impact of MAPK pathway pathogenic variantsSemantic proximity Read ↗

BRAF Mutations: Oncogenic Drivers in Solid TumorsSemantic proximity Read ↗

Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma NetworkSemantic proximity Read ↗

Next-Generation Sequencing for Patients with Sarcoma: A Single Center ExperienceSemantic proximity Read ↗

Excellent Response to MEK Inhibition in an AGK-BRAF Gene Fusion Driven Carcinoma: Case Report and Literature Review.Semantic proximity Read ↗

Current management of neurotrophic receptor tyrosine kinase fusion-positive sarcoma: an updated reviewSemantic proximity Read ↗

RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibition.Semantic proximity Read ↗

Tissue-Specific Mutations in BRAF and EGFR Necessitate Unique Therapeutic Approaches.Semantic proximity Read ↗

Trametinib for NRAS-mutated tumors: Results from the Drug Rediscovery Protocol.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.